Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin

Neurologia Medico-Chirurgica

Volumn 46, Issue 10, 2006, Pages 485-489

  Ochiai, Hidenobu ^a,b,c   Pernell, Chris T ^a   Archer, Gary E ^a   Chewning, Tracy A ^a   McLendon, Roger E ^a   Friedman, Henry S ^a   Sampson, John H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIYAZAKI   (Japan)

^c MIYAZAKI PREFECTURAL MIYAZAKI HOSPITAL   (Japan)

Author keywords

9 nitro camptothecin; Glioblastoma multiforme; Intrathecal therapy; Leptomeningeal tumor; Neoplastic meningitis; Topoisomerase I inhibitor

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; RUBITECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MEDICAL ASSESSMENT; MENINGITIS; NONHUMAN; RAT; SURVIVAL; TOXICITY TESTING; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DISEASE MODELS, ANIMAL; GLIOBLASTOMA; INJECTIONS, SPINAL; MENINGITIS; RATS; RATS, NUDE;

EID: 33750503834     PISSN: 04708105     EISSN: 13498029     Source Type: Journal    
DOI: 10.2176/nmc.46.485     Document Type: Article

References (31)

1. Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD: Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1. Clin Cancer Res 5: 2646-2652, 1999
2. Archer GE, Sampson JH, McLendon RE, Friedman AH, Colvin OM, Rose M, Sands H, McCullough W, Fuchs HE, Bigner DD, Friedman HS: Intrathecal busulfan treatment of human neoplastic meningitis in athymic nude rats. J Neurooncol 44: 233-241, 1999
3. Burke TG, Mi Z: The structural basis of camptothecin interactions with human serum albumin: impact on drug stability. J Med Chem 37: 40-46, 1994
4. Fisher B, Won M, Macdonald D, Johnson DW, Roa W: Phase II study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group 9513. Int J Radiat Oncol Biol Phys 53: 980-986, 2002
5. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17: 1516-1525, 1999
6. Fuchs HE, Archer GE, Colvin MO, Bigner SH, Schuster JM, Fuller GN, Muhlbaier LH, Schold SC, Friedman HS, Bigner DD: Activity of intrathecal 4-hydroperoxycyclophosphamide in a nude rat model of human neoplastic meningitis. Cancer Res 50: 1954-1959, 1990
7. Giovanella BC, Hinz HR, Kozielski AJ, Stehlin JS, Silber R, Potmesil M: Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res 51: 3052-3055, 1991
8. Giovanella BC, Natelson E, Harris N, Vardeman D, Stehlin JS: Protocols for treatment of human tumor xenografts with camptothecins. Ann N Y Acad Sci 803: 181-187, 1996
9. Giovanella BC, Stehlin JS, Wall ME, Wani MC, Nicholas AW, Liu LF, Silber R, Potmesil M: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046-1048, 1989
10. Grossman SA, Moynihan TJ: Neoplastic meningitis. Neurol Clin 9: 843-856, 1991
11. Groves MD: The pathogenesis of neoplastic meningitis. Curr Oncol Rep 5: 15-23, 2003
12. Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, Fakih M, Zamboni WC: Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemother Pharmacol 54: 487-496, 2004
13. Kaplan EL, Meyer P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
14. Markesbery WR, Brooks WH, Gupta GD, Young AB: Treatment for patients with cerebral metastases. Arch Neurol 35: 754-756, 1978
15. Meek JL, Neff NH: Is cerebrospinal fluid the major avenue for the removal of 5-hydroxyindoleacetic acid from the brain? Neuropharmacology 12: 497-499, 1973
16. Nishikawa R, Ji XD, Harmon RC, Lazar CS, Gill GN, Cavenee WK, Huang HJ: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci U S A 91: 7727-7731, 1994
17. Ochiai H, Moore SA, Archer GE, Okamura T, Chewning TA, Marks JR, Sampson JH, Gromeier M: Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin Cancer Res 15: 4831-4838, 2004
18. Olson ME, Chernik NL, Posner JB: Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 30: 122-137, 1974
19. Ongerboer de Visser BW, Somers R, Nooyen WH, van Heerde P, Hart AAM, McVie JG: Intraventricular methotrexate therapy of leptomeningeal metastasis from breast carcinoma. Neurology 33: 1565-1572, 1983
20. Pantazis P, Early JA, Kozielski AJ, Mendoza JT, Hinz HR, Giovanella BC: Regression of human breast carcinoma tumors in immunodeficient mice treated with 9-nitrocamptothecin: Differential response of nontumorigenic and tumorigenic human breast cells in vitro. Cancer Res 53: 1577-1582, 1993
21. Pantazis P, Early JA, Mendoza JT, Dejesus AR, Giovanella BC: Cytotoxic efficacy of 9-nitrocamptothecin in the treatment of human malignant melanoma cells in vitro. Cancer Res 54: 771-776, 1994
22. Pantazis P, Kozielski AJ, Mendoza JT, Early JA, Hinz HR, Giovanella BC: Camptothecin derivatives induce regression of human ovarian carcinomas grown in nude mice and distinguish between non-tumorigenic and tumorigenic cells in vitro. Int J Cancer 53: 863-871, 1993
23. Potmesil MB, Giovanella BC, Liu LF, Wall ME, Silber R, Stehlin JS, Hsiang YH, Wani MC: Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10, 11-methylendioxy camptothecins, in Potmesil MB, Kohn KW (eds): DNA Topoisomerases in Cancer. New York, Oxford University Press, 1991, pp 299-311
24. Potmesil MB, Giovanella BC, Wall ME, Liu LF, Silber R, Stehlin JS, Wani MC, Hochster H: Preclinical and clinical development of DNA topoisomerase I inhibitors in the United States, in Andoh T, Ikeda H (eds): Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy. Nagoya, CRC Press, 1993, pp 301-311
25. Raymond E, Campone M, Stupp R, Menten J, Chollet P, Lesimple T, Fety-Deporte R, Lacombe D, Paoletti X, Fumoleau P: Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme. Eur J Cancer 38: 1348-1350, 2002
26. Sampson JH, Archer GE, Villavicencio AT, McLendon RE, Friedman AH, Bishop WR, Bigner DD, Friedman HS: Treatment of neoplastic meningitis with intrathecal temozolomide. Clin Cancer Res 5: 1183-1188, 1999
27. Theodore WH, Gendelman S: Meningeal carcinomatosis. Arch Neurol 38: 696-699, 1981
28. Verschraegen CF, Gilbert BE, Loyer E, Huaringa A, Walsh G, Newman RA, Knight V: Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(s)-camptothecin in patients with advanced pulmonary malignancies. Clin Cancer Res 10: 2319-2326, 2004
29. Verschraegen CF, Jaeckle K, Giovanella B, Knight V, Gilbert BE: Alternative administration of camptothecin analogues. Ann N Y Acad Sci 922: 237-246, 2000
30. Wall ME, Wani MC, Cook CE, Palmer KH, McPhail AT, Sim GA: Plant anti-tumor agents I. The isolation and structure of camptothecin, a novel alkaloidal leukemic and tumor inhibitor from Camptotheca acuminata. J Am Chem Soc 88: 3888-3890, 1966
31. Wasserstrom WR, Glass JP, Posner JB: Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients. Cancer 49: 759-772, 1982